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1. Introduction 
Bone and soft tissue infections are serious problems in orthopedic and reconstructive 
surgery. Especially, chronic osteomyelitis is a difficult infection to treat and eradicate. 
Long term parenteral antibiotics with multiple surgical debridements are often required 
for effective therapy (Cierny & Mader, 1984). Therefore, it is understandable that 
continuous efforts are being made and complete one or other element in the treatment of 
bone and soft tissue infections. 
There is a long history of local antibiotic use for the treatment of bone and soft tissue 
infections. During World War I, Alexander Fleming observed that locally applied antiseptics 
failed to sterilize chronically infected wounds, but they did reduce the burden of bacteria 
(Fleming, 1920). In 1939, the instillation of sulfanilamide crystals, along with thorough 
debridement, hemostasis, primary closure and immobilization, resulted in a reduced 
infection rate for open fractures (Jensen et al, 1939). As additional systemic antimicrobial 
agents became available, interest in the topical treatment of wounds waned, but the 
management of established osteomyelitis remained problematic. In the 1960s, the method of 
closed wound irrigation-suction was popularized as a method which could be used to 
deliver high concentrations of an antibiotic after debridement (Dombrowski & Dunn, 1965). 
An alternative method for delivering high concentrations of an antibiotic to sites of lower 
extremity osteomyelitis was isolation and perfusion (Organ, 1971). 
The delivery of local antibiotics for the treatment of musculoskeletal infection has become 
increasingly popular for a variety of reasons. The basis for developing and using local 
antibiotic delivery systems in the treatment of bone and soft tissue infection is either to 
supplement or to replace the use of systemic antibiotics. High local levels of antibiotics 
facilitate delivery of antibiotics by diffusion to avascular areas of wounds that are 
inaccessible by systemic antibiotics and in many circumstances the organisms that are 
resistant to drug concentrations achieved by systemic antibiotic are susceptible to the 
extremely high local drug concentrations provided by local antibiotic delivery. 
The local use of antibiotics to prevent and treat bone and soft tissue infections was revived 
in Germany with the widespread use of prosthetic joint replacement, a situation in which 
infections were not anticipated consequence of trauma or sepsis but a devastating 
complication of elective surgery (Buchholz & Engelbrecht, 1970). However, it is from the 
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year 2000 that research on local delivery of antibiotics to bone has gained considerable 
attention. Note that the numbers of publications in the last five years are double and 
decuple published in earlier decades (Soundrapandian et al, 2009). 
Bacterial infection in orthopedic and reconstructive surgery can be devastating, and is 
associated with significant morbidity and poor functional outcomes (Haddad et al, 2004). 
Operative treatments (excision of infected and devascularized tissues, obliteration of dead 
space, restoration of blood supply and soft tissue coverage, stabilization and reconstruction 
of the damaged bone), removal of all foreign bodies and systemic antimicrobial therapy are 
three crucial components of the treatment of these cases (Lazzarini et al, 2004). A long-term 
course of systemic antibiotherapy has been considered essential, but these prolonged 
therapies can result in side effects or toxicity. In order to achieve therapeutic drug 
concentration in the affected area, high systemic doses are generally required which can 
further worsen toxic side effects (Nandi et al, 2009). Antibiotic treatment may be inadequate 
or ineffective in patients with poorly vascularized infected tissues and osteonecrosis, which 
is often present in cases of osteomyelitis. Moreover, normal doses of systemic antibiotics 
may be insufficient to breach the glycocalyx or biofilm produced by the infecting bacteria 
(El-Husseiny et al, 2011). Despite intensive therapy, advances in surgical techniques, and 
development of new antimicrobials, relapse rate are still significant and treatment of bone 
and soft tissue infections remain challenging. 
New methods such as local delivery of antibiotics have evolved in an attempt to improve 
the prognosis of patients with musculoskeletal infections. The use of local antibiotic delivery 
system has become an accepted treatment method that continues to evolve for a variety of 
reasons. There has been an explosion of new technologies that are designed to facilitate the 
delivery of local antibiotics in new and creative ways. The primary reason for using these 
local antibiotic delivery vehicles is the ability to achieve very high local concentrations of 
antibiotics without associated systemic toxicity. In the typical infected wound environment, 
which frequently has zones of avascularity, the ability to achieve high levels of antibiotics in 
these otherwise inaccessible areas is highly desirable (Cierny, 1999). Additional reasons for 
use of these delivery vehicles include the desire to treat remaining plactonic organisms and 
sessile organisms in biofilms more effectively with high concentrations of antibiotics 
(Hanssen et al, 2005). Because bone regeneration often is required as a part of the treatment 
plan, a recent trend has been simultaneously to provide a frame work of osteoinductive and 
osteoconductive materials along with antibiotics (Gitelis & Brebach, 2002).  
Despite the rapid acceptance of these antibiotic delivery vehicles, there are many 
unanswered questions related to their use, particularly when viewed within the 
environment of biofilms. Considerable investigation and development still are required to 
develop the necessary data to help determine a number of unknown variables associated 
with the use of local antibiotic delivery systems. In the application of a local antibiotic 
therapy for bone and soft tissue infections the following aspects should be considered: a) 
delivery technique; b) type of antibiotic that can be used; c) pharmacokinetics; d) possibility 
of application to a coating and to fillers; e) possibility of combination with osteoconductive 
and osteoinductive factors; f) use as prophylaxis and/or therapy; g) drawbacks.  
This review introduces bone and soft tissue infection-its present options for drug delivery 
systems and their limitations, and the wide range of carrier materials and effective drug 
choices. Also, I will describe and contrast the different local antibiotic delivery vehicles to 
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provide a context for their current clinical use and to discuss the emerging investigate and 
developmental directions of these biomaterials. 
2. Criteria for the production of a local delivery system for antimicrobial agents 
Despite the reduction in the risk of contamination due to improved material, implant, and 
clean room technique as well as peri-operative antibiotic prophylaxis, infections still remain 
a feared complication in orthopedic and reconstructive surgery (Taylor, 1997). In many 
surgical disciplines, topical administration of antibacterial drug is not possible or 
practicable, and achieving of a sufficient antibacterial dose by systemic delivery may lead to 
adverse reactions negatively influencing overall patient’s c by conditions. Especially the use 
of specific antibiotics may be limited by their high cumulative cell and organ toxicity 
(Ruszczak & Friess, 2003). Moreover, insufficiency in local blood supply due to post-
traumatic or post-operative tissue damage as well as inadequate tissue penetration or 
bacterial resistance increase the local ineffectiveness of systemic antibiotic therapy, both in 
terms of preventive or curative drug administration (Mehta et al, 1996). This dilemma can be 
resolved by local delivery of antibiotics. 
The ideal local drug delivery system has been a pursuit of scientists and physicians for the past 
fifty years. The concept of delivering drugs locally to the area of disease rather than through 
the systemic circulation without the concomitant secondary systemic complications is 
appealing both physiologically and psychologically (Nelson, 2004). The ideal local antibiotic 
delivery system would produce high antibiotic levels at the site of infection and safe drug 
levels in the systemic circulation. Antibiotic levels would need to be controlled to allow the 
systemic to be either therapeutic, bellow the toxic level, or absent, and to allow these features 
to be controlled independently from each other. Furthermore, the antibiotic elution curves, the 
factors that influence elution, and the most suitable local delivery system for the environment 
into which the material is to be placed, would need to be known. These materials would need 
to be easily placed, easily removed or changed, patient friendly and inexpensive. According to 
Hanssen, the ideal local antibiotic delivery system “would provide a more efficient delivery of 
higher levels of antibiotics to the site of infection and yet minimize the risks of systemic 
toxicity associated with traditional methods of intravenous antibiotics” (Hanssen, 2005). 
2.1 Carrier materials for local antibiotic delivery 
The consequent need for local drug delivery has been recognized since many years. During 
the last decades, different forms of local antibiotic delivery have been used. The most 
common and simple way was to spread the drug in a powder form over the wound area 
after an extensive debridement and before wound closure (Rushton, 1997). Consequently, 
high local concentrations for a short period of time are achieved which potentially result in 
tissue damage. Another approach was to applied antibiotics in liquid form by injection or 
irrigation or, to extend the effectiveness by continuous perfusion. However, this method is 
labor intensive and requires experienced nursing staff to avoid leakage and drain blockage. 
Furthermore, the use of implantable pumps which can be refilled percutaneously is 
described (Perry & Pearson, 1991). An additional method used was to soak the cotton gauze 
or linen operative material with the antibiotic and leave it in the wound until the final 
closure. This procedure is still in use in many countries to minimize the post-operative risk 
of infection, e.g. in dirty abdominal wounds or in trauma patients.  
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Although the ideal local antibiotic delivery system has not been discovered, several 
promising materials are present in modern research. The most common carrier systems of 
antibiotics that successfully release the drug according to prescribed dosage are listed in 
Table 1. 
Carrier System Antibiotic Released References 
Non-biodegradable 
1. Bone cement Gentamicin 
Baker & Greenham, 1988; 
Buchholz et al, 1984 
 Vancomycin Kuechle et al, 1990 
 Cefazolin Marks et al, 1976 
 Ciprofloxacin Tsourvakas et al, 2009 
2. Bone cement beads Gentamicin 
Buchholz et al, 1984; 
Mendel et al, 2005 
 Tobramycin Seligson et al, 1993 
 Cefuroxime Mohanty et al, 2003 
 Vancomycin Chohfi et al, 1998  
Biodegradable 
1. Plaster of Paris pellets 
Gentamicin Santschi & 
McGarvey, 2003 
 
 Teicoplanin Dacquet et al, 1992 
2. Collagen-Sponge Gentamicin Ruszczak & Friess, 2003 
3. Fibrin-sealant Cefazolin Tredwell et al, 2006 
 Ciprofloxacin Tsourvakas et al, 1995 
4. Hydroxyapatite blocks Vancomycin Shirtliff et al, 2002 
5. Polylactide/polyglycolide 
implants 
Gentamicin Garvin et al, 1994b 
 Ciprofloxacin Koort et al, 2008 
 Vancomycin Calhoun & Mader, 1997 
6. Dilactate polymers Fluoroquinolones 
Dounis et al, 1996; 
Kanellakopoulou et al, 
1999 
7. Cancellous bone 
Vancomycin, 
Ciprofloxacin 
Witso et al, 2000 
8. Calcium Sulfate Tobramycin Nelson et al, 2000 
9. Calcium phosphate cement Teicoplanin Lazarettos et al, 2004 
Miscellaneous 
1. Fibres Tetracycline Tonetti et al, 1998 
2. Chitosan Vancomycin Chevher et al, 2006 
3. Biomedical polyourethanes Gentamicin, Ciprofloxacin Schierholz et al, 1997 
Table 1. Carriers used for local delivery of antibacterial agents 
Drug delivery carriers developed for local delivery of antibiotics can be divided into non-
biodegradable and biodegradable carriers (Kanellakopoulou & Giamarellos-Bourboulis, 
2000). Non-biodegradable delivery systems such as polymethylmethacrylate (PMMA) 
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beads containing gentamicin have been approved for use in treatment of osteomyelitis in 
Europe (Klemm, 2001; Seligson et al, 1993). Antibiotic-loaded bone cement represent the 
current gold standard for local antibiotic delivery in orthopedic surgery (Nelson, 2004). 
This product has been proven to be efficacious but suffers from the major drawback of 
requiring subsequent operation to remove the bone cement beads at the completion of 
antibiotics release. 
In recent years, various biodegradable delivery systems have been developed and evaluated 
for local delivery of antibiotics in the treatment of bone and soft tissue infections (Garvin et 
al, 1994b; Gursel et al, 2000). One of the primary advantages of a biodegradable system is the 
avoidance of secondary surgical procedures to remove foreign materials, such as bone 
cement, once antibiotic elution has ceased. Biodegradable implants could provide high local 
bactericidal concentrations in tissue for the prolonged time needed to completely eradicate 
the infection and the possibility to match the rate of implant biodegradability according to 
the type of infection treated (Kanellakopoulou & Giamarellos-Bourboulis, 2000). 
Biodegradation also makes surgical removal of the implant unnecessary. The implant can 
also be used initially to obliterate the dead space and, eventually to guide its repair. 
Additional possibilities with the use of biodegradable systems include variation in the 
magnitude and duration of antibiotic delivery as well as the potential for purposely 
adjusting the wound environment with breakdown products of some biodegradable 
materials (Hanssen, 2005). 
Additional methods have included adding antibiotics to bone graft and to bone substitutes 
(Li & Hu, 2001; Shinto et al, 1992; Witso et al, 2000) or other naturally occurring polymers 
(Kawanabe et al, 1998) whereby the antibiotic is adsorbed to the surface of these materials 
and is then released into the wound environment. These materials can be include to the 
biodegradable antibiotic carriers. 
The major drawback associated with non-biodegradable systems is the need to remove from 
the application site upon completion of their task. This removal surgery is usually more 
difficult than the implantation because of local tissue scaring and adhesion and may lead to 
postoperative infection due to both the patient local and systemic condition. In addition, the 
second procedure poses the risk of additional pain, anesthetic complications, and inferring 
extra costs. Recently, a Dutch group of scientists has found that despite of antibiotic release, 
cement beads act as a biomaterial surface at which bacteria preferentially adhere, grow and 
potentially develop antibiotic resistant (Neu et al, 2001).  
2.2 Antibiotic selection 
In order to select the appropriate antibiotic, an understanding of the microbiology of bone 
and soft tissue infections is imperative. Normal bone is highly resistant to infection, which 
can only develop as a result of trauma, very large inocula, or due to the presence of foreign 
material. Irrespective of the advancement in making surgeries and prosthesis, available 
sterile, and achieving aseptic conditions in operation theatres , infection associated with 
major trauma or surgeries are still unavoidable. Due to their application for prophylaxis and 
therapeutic antibiotics need to be applied to bone in every case of trauma or surgery, in 
addition to cases of bone and soft tissues infections. When the microbial load has crossed a 
critical density, they form biofilms that are quite hard for antibiotics to penetrate, often 
resulting in relapse of infection (Fux et al, 2005). Very high concentrations of antibiotics are 
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required to eradicate them, which could hardly be attained by conventional routes of 
delivery without serious side effects. 
The most commonly described microbes to cause bone and soft tissue infections, especially 
chronic osteomyelitis, are staphylococcus aureus; Group A beta hemolytic streptococcus and 
gram-negative bacteria, particularly Enterobacteriaceae and Pseudomonas aeruginosa 
(Galanakis et al, 1997; Rissing et al, 1997). 
Numerous of antibiotics are available for use in antibiotic impregnated carriers. Considering 
the above criteria and on bacteriological finding in bone and soft tissue infections, the most 
acceptable agents in local delivery systems are aminoglycosides and to a lesser extent 
various β-lactam agents and quinolones (Rushton, 1997). A combination therapy of 
antibiotics is useful to reduce the toxicity of individual agents, to prevent the emergence of 
resistance and to treat mixed infections involved in chronic osteomyelitis (Mader et al, 1993). 
However, specific characteristics should be considered before the antimicrobial agents 
selected for use in local delivery systems: the antibiotic should be stable at body temperature 
and water soluble to ensure diffusion from the carrier; be active against the most common 
bacterial pathogens involved in bone and soft tissue infections; be locally released at 
concentrations exceeding several times (usually 10 times) the minimum inhibitory 
concentration (MIC) for the concerned pathogens; be unable to enter in systemic circulation; 
have a low rate of allergic reaction; a low rate of primary resistance; not produce supra 
infection and be readily available in powder form (Kobayashi et al, 1992; Popham et al, 
1991). The choice of different classes of antibiotics for clinical use must be made according to 
a microbiologic sensitivity test (Popham et al, 1991; Ueng et al, 1997). 
Antibiotics in general are hydrophilic drugs, hardly exhibit stability problems (except a few 
as cephalosporins) making them suitable to load with any kind of composite. Release of 
antibiotics shall depend on various factors. Release of the antibacterial agent in such systems 
is governed by the rate of dissolution of the drug in its matrix allowing its penetration 
through the pores of the carrier. For highly soluble agents, e.g. β-lactams agents, the amount 
of released drug depends on the surface area of the carrier and on the initial concentration of 
the drug in the prepared system. For relatively insoluble agents, e.g. quinolones, the rate of 
drug release depends on the porosity of the matrix and on dissolution of the drug in the 
matrix (Allababidi & Shah, 1998). However, insufficient release of antibiotics on the basis of 
time and concentration could lead to development of resistant strains and growth of 
microorganisms on the surface of the scaffolds (Soundrapandian et al, 2009).  
3. Non-biodegradable systems 
Antibiotic-impregnated non-biodegradable beads mainly polymethylmethacrylate (PMMA) 
have been widely used for the local administration of antibiotics. Buchholz and Engelbrecht 
in 1970 proposed delivering antibiotics to an infected site via elution of antibiotics from 
antibiotic-impregnated cement placed adjacent to the site of infection. The use of antibiotic-
impregnated polymethylmethacrylate (PMMA) cement bead for the treatment of bone and 
soft tissue infections has many theoretical advantages. The beads, which release antibiotics 
by passive diffusion, combine with high local concentrations with low systemic levels of the 
antibiotic (Henry & Galloway, 1995), leading to more effective killing of the organisms and 
less risk of systemic toxicity. In addition, the beads can fill the dead space that may be left 
after debridement of infected tissue (Patzakis et al, 1993). 
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3.1 Antibiotic-loaded bone cement (PMMA) 
Antibiotic impregnated beads have been employed in the treatment of bone and soft 
tissue infections for nearly 30 years; their use is well established in many European 
centers (Jenny, 1988). For the first time, antibiotic-loaded bone cement was used as a 
prophylactic agent against deep bone infections in orthopedic endoprosthetic surgery in 
human patients (Buchholz et al, 1984). Since then antibiotic-loaded bone cement has been 
an effective method for providing sustained high concentrations of antibiotics locally 
when used in numerous types of bone and soft tissue infections (Calhoun & Mader, 1989; 
Josefsson et al, 1990). Polymethylmethacrylate (PMMA) exist in two forms: that of 
antibiotic-impregnated bone cement applied in arthroplasties and antibiotic-impregnated 
bead chains for musculoskeletal infections (Henry & Galloway, 1995). The success of these 
carriers depend on two factors: PMMA does not usually trigger any immune response 
from the host and the form of a bead confers a wide surface area, allowing rapid release of 
the antibiotic. 
Several factors influence the elution of antibiotics from PMMA cement. In addition to the 
type of antibiotic used, the type of cement also influences elution (Marks et al, 1976). Factors 
that increase the porosity of the cement (such as the addition of dextran or higher 
concentrations of antibiotic) also increase elution (Patzakis & Wilkins, 1989). Walenkamp in 
1989, showed that the size of the bead influenced the amount of antibiotic that can be eluted. 
Small or mini beads provide better elution than larger beads, probably because of a more 
favorable surface to volume ratio (Holtom et al, 1998). Finally, the turnover of the fluid 
surrounding the beads will influence the local concentration as well as the maximum 
amount of antibiotic eluted. 
Polymethylmethacrylate cement is available in various commercial and non-commercial 
brands and in-vitro elution of antibiotics from these varies between brands (Greene et al, 
1998). Commercially available beads have a consistent diameter of 7mm and are available in 
stands of 10 or 30 (Nelson et al, 1992). Noncommercial preparations are generally prepared 
by the surgeons themselves. The main disadvantages associated with beads are improper 
mixing of antibiotic into the beads and a lack of the uniform size of bead, resulting in lower 
antibiotic availability (Nelson et al, 1992). Selection of antibiotic in commercially prepared 
beads depends on its stability at the high temperatures (up to 100ºC) at which 
polymerization of bone cement occurs. The aminoglycosides are heat stable and are thus 
extensively used in these preparations. It has been documented for human being and in-
vitro studies that elution of antibiotics from PMMA is bimodal (Henry et al, 1991). 
Approximately 5% of the total amount of antibiotic is released within the first 24 hours from 
the surface of beads or rods, followed by a sustained elution of antibiotic that diminishes 
during subsequent weeks or months. Elution properties of polymethylmethacrylate bone 
cement depend on the type of PMMA, type and concentration of antibiotic and structural 
characteristics of the bead or rods (Henry et al, 1991). Gas sterilization does not affect the 
properties of antibiotics or elution properties of PMMA (Henry et al, 1993). 
There have been many in-vitro studies on the diffusion or elution of antibiotics from 
polymethylmethacrylate bone cement. Several different antimicrobial agents have been 
studied, including the aminoglycosides, primarily gentamicin but also tobramycin, 
amikacin and streptomycin (Greene et al, 1998; Masri et al, 1995; Wahlig et al, 1978), 
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cephalosporins including cefazoline, cefotaxime, ceftriaxone and ceftazidime (Alonge & 
Fashina, 2000; Tomczak et al, 1989; Wilson et al, 1988), vancomycin (Kuechle et al, 1991) 
and ciprofloxacin (Tsourvakas et al, 2009). All antimicrobial agents go through an initial 
phase during which the concentration of fluid surrounding the beads or cement spacers is 
very high, followed by a gradual decrease to sustained low levels for many weeks or 
months. Although there are differences in elution between each different antimicrobial 
agent, all seem to have adequate elution for the treatment of bone and soft tissue 
infection, but the length of time that the drug levels remain above the minimum 
inhibitory concentration for the target organism (usually Staphylococcus aureus) varies 
depending on the drug selected and the conditions of the experiment. Cumulative data on 
the in-vitro elution of antibiotics in polymethylmethacrylate bone cement are presented in 
table 2, where it is clearly shown that both aminoglycosides and quinolones are released 
at very high concentrations, but the peak of release occurs on the first day. As the 
viscosity of PMMA decreases, the amount of released antibiotic increases (Bunetel et al, 
1990). The same first day peak was also documented for tobramycin and vancomycin 
(Brien et al, 1993); the release lasted for a total period of only one week. 
 
Antibiotic-loaded 
Duration of 
release 
Peak of release 
(μg/ml) Study 
PMMA (days) /day of peak  
Gentamicin 56 318.6/1 Hoff et al, 1981  
Tobramycin 220 >250/1 Mader et al, 1997 
Clindamycin 220 >250/1 Mader et al, 1997 
Vancomycin 12 >200/1 Mader et al, 1997 
Cefazolin 28 250/1 Adams et al, 1992 
Penicillin 91 199.5/1 Hoff et al, 1981 
Ciprofloxacin 360 80.8/1 Tsourvakas et al, 2009 
Amikacin 5 200/1 Kuechle et al, 1990 
Table 2. Characteristics of the in-vitro elution of different antibiotics from PMMA bone 
cement 
To achieve adequate killing of bacteria, beads should not be used in combination with an 
irrigation system, and moisture should be excluded by artificial skin. With these precautions 
the amount of gentamicin releasd by the bone cement beads does not exceed 25% of the total 
amount implanted (Rushton, 1997). In chronic osteomyelitis, healing of the wound expected 
within 10 days but PMMA beads may remain implanted for up to 4 weeks, after his surgical 
removal is necessary followed by osseous reconstructive surgery. The need for removal is 
the major disadvantage of the beads, although in some patients small chains of beads be 
removed in the ward via a small skin incision (Walenkamp, 1997). 
Antibiotic-loaded bone cement can be applied either in infected arthroplasties or as surgical 
prophylaxis during joint arthroplasties. Cumulative results of clinical studies involving its 
application for both purposes are given in table 3. 
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Study 
Purpose of 
application 
Patients 
Favorable 
outcome 
(%) 
Follow-up 
( months) 
Josefsson et al, 1990 
Prophylaxis in total 
hip arthroplasty 
1688 99.2 60 
Garvin et al, 1994a 
Periprosthetic hip 
infection  
40 95 17 
Hanssen et al, 1994 
Infected knee 
prosthesis  
183 84.2 93 
Whiteside, 1994  
Infected knee 
prosthesis  
33 96.9 24 
Raut et al, 1995  
Infected knee 
prosthesis  
86 89.6 52 
Cho et al, 1997  
Chronic 
osteomyelitis  
31 87 36 
Table 3. Cumulative data from clinical trials with antibiotic-loaded PMMA bone cement 
The primary basis for use of antibiotic-loaded polymethylmethacrylate bone cement as a 
prophylactic method to reduce the prevalence of deep periprosthetic infection has been the 
clinical experience obtained over the past three decades combined with data from several 
experimental studies (Jiranek et al, 2006). Gentamicin, cefuroxime and tobramycin have 
been the antimicrobials most commonly admixed into PMMA in clinical studies worldwide 
(Chiu et al, 2002; Engesaeter et al, 2003; Malchau et al, 1993). In United States, tobramycin 
has been used most commonly, primarily because the product is available in powdered 
form. Of the three antibiotics, gentamicin has been used most frequently and studied most 
extensively overall (Hanssen, 2004). 
In a large retrospective study, data on 22170 primary total hip replacements from the 
Norwegian Arthroplasty Register during the period of 1987 to 2001 were analyzed 
(Engesaeter et al, 2003). Patients who received only systemic antibiotic prophylaxis had a 1.8 
times higher rate of infection than patients who received systemic antibiotic prophylaxis 
combined with gentamicin-loaded bone cement. Another retrospective study, of 92675 hip 
arthroplasties listed in the Swedish Joint Registry, presented similar conclusions, with the 
use of antibiotic-loaded bone cement favored for both primary and revision hip 
arthroplasties (Malchau et al, 1993). 
Recently, prosthesis of antibiotics loaded acrylic bone cement consisting of an acetabular 
cup filled with antibiotic loaded polymethylmethacrylate bone cement was developed for 
the treatment of infections at the site of total hip arthroplasty accompanied by the 
extensive loss of the proximal part of the femur (Younger et al, 1998). The antibiotic 
usually impregnated is tobramycin or vancomycin with an elution of the former at intra-
articular concentrations between 4.35 and 123.88 mg/L and remains undetected in the 
latter (Masri et al, 1998). This has resulted in a success rate of 94% in 61 patients after an 
average follow-up of 43 months. Polymethylmethacrylate bone cement beads impregnated 
with vancomycin were successfully used for the treatment of osteomyelitis of the pelvis 
and of the hip (Ozaki et al, 1998). 
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The primary concern regarding antibiotic-loaded acrylic bone cement include the potential for 
detrimental effects on the mechanical or structural characteristics of polymethylmethacrylate 
bone cement when antibiotic are admixed. The addition of >4.5g of gentamicin powder per 
40g package of cement powder or the addition of liquid antibiotics causes a decrease in 
compressive strength to a level below American Society for Testing and Materials standards 
(Lautenschlager et al, 1976). The use of high-dose antibiotics in acrylic bone cement spacers 
(>2g of antibiotic powder per 40g of acrylic bone cement powder) implanted in staged revision 
procedures can lead to substantial cost savings to the hospital and improvement in patient 
care. However, the routine use of high-dose antibiotics in cement employed for fixation of 
prostheses is not supported by evidence (Jiranek et al, 2006). 
Another basic concern regarding antibiotic-loaded polymethylmethacrylate bone cement 
include the potential for development of drug-resistant bacteria. Many of the bacterial 
pathogens involved in bone and soft tissue infections, particularly Staphylococcus 
epidermidis, produce a biofilm that limits the activity of antibiotics (Gracia et al, 1998). The 
biofilm, known as the extracellular slime of glycocalyx, is produced by strains of 
Staphylococcus aureus and Staphylococcus epidermidis, it also provides these strains with 
the capacity to adhere the foreign materials, such as the acrylic bone cement beads (Bayston 
& Rogers, 1990). Consequently, despite adequate killing of these micro-organisms by in-
vitro elution of antibiotic in close proximity to the beads, the same micro-organisms survive 
on their surface (Kendall et al, 1996). This stable adherence might provide a mechanism of 
recurrence of the infection and of development of resistance, since small colony variants of 
Staphylococcus aureus resistant to gentamicin have been isolated from the wounds of 
patients with bone and soft tissue infections treated with gentamicin-impregnated acrylic 
bone cement beads (vonEiff et al, 1997). In a report from the Ohio State University 
Medical Center, the overall rate of infection decreased with the introduction and use of 
antibiotic-loaded acrylic bone cement; however, the prevalence of aminoglycoside-
resistant bacteria, particularly in Staphylococcus aureus and coagulase-negative 
staphylococcal infections, increased (Wininger & Fass, 1996). Because of the considerable 
data suggesting the potential for the development of bacterial antibiotic resistance, 
antibiotic-loaded polymethylmethacrylate bone cement should not be used routinely for 
prophylaxis. Rather, it should be used for prophylaxis only when there are clear 
indications, such as a high-risk primary procedure or a high-risk revision arthroplasty. 
Vancomycin should not be used as a primary agent for prophylaxis because of the 
emergence of resistant organisms and the need to reserve this antibiotic for patients who 
require it for treatment (Hanssen & Osmon, 1999). 
4. Biodegradable materials 
A variety of bone cement alternatives have been used experimentally and clinically as local 
antibiotic delivery vehicles and there are many additional products in development. 
Currently, there are no FDA-approved biodegradable materials available for use to treat 
established musculoskeletal infection (Nelson, 2004). 
Biodegradable implants could provide high local bacteridical concentrations in tissue for the 
prolonged time needed to completely eradicate the infection and the possibility to match the 
rate of implant biodegradability according to the type of infection and the possibility to 
match the rate of implant biodegradability according to the type of infection treated. 
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Biodegradation also makes surgical removal of the implant unnecessary. The implant can 
also be used initially to obliterate the dead space and, eventually, to guide its repair. 
Furthermore, secondary release of the antibiotic may occur during the degradation phase of 
the carrier, which could increase antibacterial efficacy compared to non-biodegradable 
carriers (Nandi et al, 2009). 
The biodegradable antibiotic delivery materials have been classified into four broad 
categories: bone graft and bone substitutes, protein-based materials (natural polymers), 
synthetic polymers and miscellaneous biodegradable materials (McLaren, 2004). Within 
these four categories there are several mechanisms of antibiotic release such as the first 
order kinetics associated with antibiotics attached by surface adsorption and variable 
antibiotic release rates that are observed with products whereby antibiotics are admixed 
within the substance of the biomaterial (Hanssen, 2005). In vitro and in vivo elution of 
antibacterial agents from biodegradable materials are show in tables 4 and 5. 
 
Study Carrier Antibiotic 
Duration of 
release (days) 
Witso et al, 2000 Bone-graft Vancomycin 7 
  Ciprofloxacin 7 
Jia et al, 2010 Calcium Sulfate Teicoplanin 29 
Wachol-Drewek et 
al, 1996  
Collagen Sponge Gentamicin 4 
  Vancomycin 2 
Tsourvakas et al, 
2009 
Fibrin-clot Ciprofloxacin 60 
Garvin et al, 1994b  Synthetic Polymers Clindamycin 38-50 
   Tobramycin 36-75 
  Vancomycin 38-51 
Kanellakopoulou et 
al, 1999 
Polylactate Ciprofloxacin 51-350 
  Pefloxacin 56-295 
Dounis et al, 1996 Polylactate Fleroxacin 56 
Santschi & 
McGarey, 2003 
Plaster of Paris Gentamicin 14 
Shinto et al, 1992 Hydroxyapatite Gentamicin 90 
 
Table 4. Cumulative data from in-vitro studies with antibiotic-loaded in biodegradable 
materials 
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Study Carrier Antibiotic 
Animal 
Model 
Duration of 
release 
(days) 
Witso et al, 2000 Bone-graft Vancomycin Rat 7 
  Ciprofloxacin  3 
Shinto et al, 1992 Hydroxyapatite Gentamicin Rat 90 
Stemberger et al, 
1997 
Collagen Sponge Gentamicin Rabbit 56 
Tsourvakas et al, 
1995 
Fibrin-clot Ciprofloxacin Rabbit 15 
Kanellakopoulou 
et al, 2000 
Lactic-acid Pefloxacin Rabbit 33 
Garvin et al, 1994b Synthetic 
Polymers 
Gentamicin Canine 42 
Koort et al, 2008 Synthetic 
Polymers 
Ciprofloxacin Rabbit 42 
Table 5. Cumulative data from in-vivo studies with antibiotic-loaded in biodegradable 
materials 
4.1 Bone grafts and bone substitutes 
Bone graft, either as autograft or allograft, as a vehicle for local antibiotic delivery, has been 
used clinically for more than twenty years (McLaren, 2004).  
Morselized cancellous bone has been used extensively as bone graft material. There are 
variations in the material that depend on the method of preparation. The use of morselized 
cancellous bone as a delivery carrier for antibiotics was developed in 1984 when there was 
limited choice in bone-grafting material and constraints related to biologic hazards were 
manageable (McLaren & Miniaci, 1986). Antibiotics can be added as a powered to 
morselized cancellous bone or by soaking the bone-graft in an antibiotic-loaded solution. 
The antibiotic is absorbed directly to the bone surfaces and subsequent release of antibiotics 
is based on first-order kinetics (McLaren, 2004). Although this clinical application protocols 
with a variety of different antibiotics, there are very little data regarding the actual 
concentration levels of the local antibiotics and the clinical effects that this practice has an 
eventual bone graft incorporation. 
In vitro elution studies (McLaren & Miniaci, 1986) and in vivo studies in a rabbit model 
(McLaren, 1988) have shown first-order kinetics for release of tobramycin during a period of 
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over three weeks. Tobramycin levels exceeded usual bacteridical concentrations for three 
weeks in the graft material implanted in a rabbit. In another study, the results showed that 
morselized bone graft can act as a carrier netilmicin, vancomycin, clindamycin and 
rifampicin in vitro and in vivo. Antibiotics levels exceeded usual bacteridical concentrations 
for seven days in the graft material implanted in a rat (Witso et al, 2000). 
Application of antibiotic impregnated autogenic cancellous bone grafting has already 
been introduced in clinical practice. Chan et al, in 1998, reported results from 36 patients 
with infected fractures resulting from traffic accidents. After surgical debridement an iliac 
cancellous bone graft was taken and mixed by the surgeon with piperacillin and/or 
vancomycin, depending on the susceptibility of the isolated infective micro-organism. The 
graft was then implanted at the site of infection inside the osseous defect, which occurred 
principally in the proximal, middle or distal segment of the left or right tibia. Four to five 
months were necessary for bone union, and the only complications presented were skin 
rashes. 
Impregnation of antimicrobial agents within osteoconductive biomaterials (calcium sulfate, 
calcium phosphate, hydroxyapatite or tricalcium phosphate) has been proposed for local 
treatment of osteomyelitis and to aid dead space management (Kawanabe et al, 1998; 
Makinen et al, 2005; Nelson et al, 2005). As a common feature, these implants show a rapid 
release of the antibiotic in a more or less controlled manner (McLaren, 2004). One of the 
benefits of this class of materials is that implantation provides the opportunity to deliver 
local antibiotics at high concentrations and simultaneously participate in the bone 
regeneration process during the time period of material degradation. These materials also 
avoid the risk of transmitting disease pathogens associated with the use of allograft bone. 
Of these materials, commercial calcium sulfate has probably been used most commonly in 
the clinical setting of osteomyelitis treatment (Gitelis & Brebach, 2002). The most 
appropriate antibiotic dosage regimen not clear however, the most common formulation 
used clinically has been 3.64% vancomycin or 4.25% tobramycin per weight (Gitelis & 
Brebach, 2002). These percentages equate to 1g of vancomycin or 1.2g for tobramycin per 
25g of calcium sulfate. Other antibiotic-loaded biomaterials being investigated in this 
category include calcium hydroxyapatites (Shirliff et al, 2002), calcium phosphates 
(Lazarettos et al, 2004), bioactive glasses (Kawanabe et al, 1998) and antibiotic loaded blood 
coated demineralized bone (Rhyu et al, 2003).  
4.2 Natural polymers (protein-based materials) 
This category includes antibiotic-loaded sponge collagen (Mehta et al, 1996; Ruszcak & 
Friess, 2003), fibrin (Tredwell et al, 2005; Tsourvakas et al, 1995), thrombin, and other 
commercially available systems that use clotted blood products. Although there are 
investigators actively involved in the use of these materials, their use as local antibiotic 
delivery vehicles is not as common as the use of antibiotic-loaded bone cement, antibiotic-
loaded bone graft substitutes in the treatment of bone and soft tissue infections. 
These materials function as delivery vehicles by providing a physical scaffold around the 
antibiotic mechanically limiting fluid flow, or by providing a protein to bind the antibiotic. 
Some data on release properties are published for all of these materials determined by either 
elution studies or by animal studies. Elution rates, tend to be rapid, leading to release of 
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essentially all of the contained antibiotic in the range of hours to a few days. Antibiotic 
release in animal models is slower. Time to release the majority of contained antibiotic 
ranges from many days to several weeks. The investigations generating these data are 
limited, using a wide spectrum of methods, making a comparison of performance of these 
materials invalid. Clinical guidelines for the amount of the material to be used and for the 
dose of the contained antibiotic are not possible (McLaren, 2004). 
Collagen sponge is the material in this group that was the best supporting data. It is a solid 
mesh of collagen-based spongy material, produced from sterile animal skin or tendo 
Achillis. Since collagen is a major component of connective tissue and the main structural 
protein of all organs, it has several desirable biological properties, including both 
biocompatibility and non-toxicity. Its ability to release drugs can be modified by changing 
the porosity of the matrix or by treating it with chemicals (Rao, 1995). It can also attract and 
stimulate the proliferation of osteoblasts, thereby promoting mineralization and the 
production of collagenous callus tissue, which aids the formation of new bone (Reddi, 1985).  
Collagen sheets with impregnated gentamicin have been used to treat chronic osteomyelitis 
(Ipsen et al, 1991). It has been commercially available in Europe for ten years and is 
produced from sterilized bovine tendon in which gentamicin is suspended. In vitro studies 
of antibiotic release from collagen sponges showed four days to complete (Wachol-Drewek 
et al, 1996). When collagen sponge is combined with liposome encapsulated antibiotics, the 
duration of time for release of the antibiotics has been reported to be up to three times 
greater that that of collagen sponge alone (Trafny et al, 1996). Polymyxin-B and amikacin 
have been shown in other laboratory experiments to have significant sustained release 
action against Pseudomonas aeruginosa when attached to type I collagen (Trafny et al, 
1995). Gentamicin impregnated collagen sponge shows up to 600 times MIC as compared to 
polymethylmethacrylate beads at 300 times MIC .It has also been observed that due to its 
release of large amounts of gentamicin the flexible gentamicin-contained collagen sponge 
proved to be superior to the rigid polymethylmethacrylate beads. Other authors conclude 
that it is an effective delivery vehicle for up to 28 days in a rabbit model (Humphrey et al, 
1998) and that it is effective clinically (Kanellakopoulou & Giamarellos-Bourboulis, 2000). 
Further characterization and technique refinement are required before it can be 
recommended as a delivery vehicle for antibiotics. Commercially prepared antibiotic-laden 
collagen sponge is not available for use in the United States. 
Fibrin sealants are topical hemostatic materials derived from plasma coagulation proteins 
that are being used increasingly in surgical procedures (Jackson, 2001). Fibrin sealants have 
great potential for the delivery of antibiotics, chemotherapy, and even growth factors at 
surgical sites (Jackson, 2001). They are biocompatible and degrade by normal fibrinolysis 
within days or weeks depending on the site. The main use of fibrin sealants has been in 
cardiovascular, thoracic, dental, plastic and reconstructive surgery. More recently, 
orthopedic procedures, such as total knee arthroplasty or hip replacement, have also been 
shown to benefit from the use of fibrin sealants (Jackson, 2001). 
Clearly, the compatibility of these materials with surgical wound sites makes fibrin sealant 
logical candidates for use as controlled-release carriers for local antibiotic delivery. It has been 
shown that antibiotics with low water solubility, such as tetracycline base, are particularly 
suited to this system (Woolveron et al, 2001), presumably because the precipitated drug 
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dissolves and diffuses slowly from the fibrin clot. Even more water-soluble antibiotics such as 
gentamicin and ciprofloxacin have been shown to release in vitro from fibrin over 5-7 days for 
gentamicin (Kram et al, 1991) and over 60 days for ciprofloxacin (Tsourvakas et al, 1995), 
although more than 66% was released in the first two days. In an animal model the maximum 
level of ciprofloxacin in bone and soft tissues, after the implantation of composite in the 
medullary canal of rabbit tibia, was obtained on the second day after implantation, and the 
drug was undetectable after ten days (Tsourvakas et al, 1995). 
Zilch and Lambiris (1986) measured the cefotaxime concentrations in both blood and wound 
drainage from 46 patients with osteomyelitis who were treated with a fibrin clot cefotaxime 
mixture injected into the bone cavity. These authors reported serum levels that were low 
within 12 hours after fibrin clot placement, but wound drainage fluid maintained high 
concentrations for more than 3 days. 
Fibrin clot antibiotic mixtures are a promising approach to providing a biocompatible tissue 
sealant with local antibiotic release that may decrease the incidence of postoperative 
infections. Further in vitro work is necessary to characterize the effect the addition of 
antibiotics has on the rate and strength of fibrin clotting. Additional in vivo data are 
necessary to determine what effect low systemic levels of antibiotics might have on 
antibiotic resistance patterns. 
4.3 Synthetic polymers 
Although collagen sponge is an established method of managing infection, there is great 
interest in developing a carrier with longer lasting effects and better penetration. 
Biodegradable synthetic polymers have been used in surgery since the 1950s as suture 
material. Advances in processing have generated stronger, more reliable synthetic polymers 
based implants for consideration as carriers (El-Husseiny et al, 2011). 
The most active area of current research using biodegradable polymers from glycolide and 
lactide is in the controlled delivery of drugs especially in antibiotics such as ampicillin, 
gentamicin, polymyxin B and quinolones (Calhoun & Mader, 1997; Kanellakopoulou et al, 
1994; Nie et al, 1995). Polylactide/polyglycolide was selected to act as a carrier because it 
undergoes a gradual degradation in a controlled manner and dissolves at physiological pH 
and removal is thus not necessary in patients who have bone and soft tissue infections 
(Nandi et al, 2009). A second advantage is that the kinetics of the release of the antibiotic can 
be modified by the selection of copolymers of varying monometric composition, polymer 
crystallinity and molecular weight as well as by alteration of the geometry of the implant. 
Finally, preliminary studies indicated that these materials is highly compatible with a wide 
variety of antibiotics and the in vivo release of antibiotics occurs for a definite time period 
with therapeutic concentrations, which may minimize slow residual release at suboptimal 
concentrations (Makinen et al, 2005).  
Polymers are available in different patterns such as polylactides, copolymers of lactide and 
glycolide, polyanhydride and polycarpolactone. Copolymers of polylactides and 
polyglycolic acid have been produced with a ratio between the two composites varying 
between 90:10 and 50:50. It has been observed from in vitro studies that the 90:10 ratio 
provides better stability, delayed decomposition and superior elution concentrations of 
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tobramycin, clindamycin and vancomycin than copolymers produced at other ratios 
(Bunetel et al, 1990). Copolymers (50:50)-gentamicin implant was significantly more 
successful than the use of the standard parenteral therapy in experimental osteomyelitis in 
canine model (Garvin et al, 1994). 
The biocompatibility of polylactide/polyglycolide acid has been well established. The tissue 
reaction to implanted materials is minimum, with the inflammatory response limited to a 
narrow region, which gradually diminishes as the polymer is desorbed (Brady et al, 1973). 
Although lactide/glycolide polymers were suggested as carriers for antibiotics thirty 
years ago (Thies, 1982), it was ten years before linked lactic acid chains were proposed as 
a drug delivery system for the treatment of bone and soft tissue infections. Wei et al in 
1991 implanted molded rods, made by heating a mixture of lactic acid oligomer and 
dideoxykanamycin B, into rabbit models. They showed that the MIC of antibiotic for the 
common causative organisms of osteomyelitis was exceeded for six weeks in the cortex, 
the cancellous bone, and in the bone marrow. Furthermore, the majority of the implant 
material has been absorbed, and the bone marrow had returned to a nearly normal state 
within nine weeks of implantation. 
Sampath et al in 1992 demonstrated an alternative method of delivering gentamicin locally 
using polymers. They prepared microcapsules composed of a polylactic acid shell containing 
gentamicin which was then compressed into the desired shape. It was noted that more 80% of 
antibiotic was released in the first three weeks in vitro. The efficacy of microcapsules in 
osteomyelitis has also been demonstrated in a study by Garvin et al, in 1994. 
The polylactate polymers achieve prolonged in vivo quinolones release at higher levels 
than the other systems and produced their peal drug release after 15 days 
(Kanellakopoulou et al, 1994). On the basis of the adequacy of elution of quinolones from 
the polylactate carrier, pefloxacin impregnated of this carrier was used for therapy of an 
experimental osteomyelitis caused by the local application of MRSA in rabbits 
(Kanellakopoulou et al, 2000). 
One of the primary drawbacks with synthetic polymers has been the difficulties associated 
with designing implants that also providing structural integrity. For this specific reason, the 
use of this category of biomaterials, like the other non-cement alternatives, has primarily 
been for the treatment of osteomyelitis. Although the structural requirements necessary for 
other applications can be accomplished for these implants initially, the process of polymer 
degradation often has led to severe loss of structural integrity during the course of treatment 
(Hanssen, 2005). 
Synthetic polymers could function as a delivery vehicle for antibiotics with further 
evaluation and development. Manipulation of the material properties and combinations of 
one or more of these material can lead to any clinically desirable release rate. Investigations 
have been exploring these variables (Ambrose et al, 2003). However, no one material has 
shown dominance with confirmatory investigations and progression in development 
towards a usable clinical preparation. There are not available for clinical use as a depot 
antibiotic delivery vehicle. This may be related in part to the economics of bringing these 
products to market premixed with antibiotic. Currently, there is no polymer available that 
can be hand mixed with antibiotics in the operating room. 
www.intechopen.com
 
Local Antibiotic Therapy in the Treatment of Bone and Soft Tissue Infections 
 
33 
4.4 Miscellaneous 
The range of different intended functions of these materials include different rates and 
timing of antibiotic release, provision of physicochemical characteristics necessary for 
osteoconduction, and provision of a scaffold that allows osteoconduction, osseous 
integration, and sufficient structural properties. 
Antibiotic loaded plaster of Paris pellets is an effective ancillary treatment in the surgery of 
infected cavities in bone. It is well tolerated and spontaneous absorbed over a period of 
weeks to months, being replaced by bone if normal architecture (Mackey et al, 1982). Many 
antibiotics can be added to plaster of Paris, such as gentamicin, fucidic acid, and teicoplanin 
(Dacquet et al, 1992; Mackey et al, 1982). 
Fibres locally releasing tetracycline hydrochloride have been successfully introduced for 
the therapy of persistent or recurrent periodontitis (Tonetti et al, 1998). Chitosan is an 
excellent biomaterial with biodegradable and immunologic activity, the gentamicin 
loaded chitosan bar seems to be a clinically useful method for the treatment of bone and 
soft tissue infections (Aimin et al, 1999). Different types of gel like hyalouronic acid 
(Matsuno et al, 2006), fibrin gel with bone marrow derived mesenchymal stem cells (Hou 
et al, 2008), and monoolein-water gels (Ouedraogo et al, 2008) have been used as an 
alternative treatment for bone and soft tissue infections. 
Some unconventional marine biomaterials like sponge skeleton, coral, snail slime with 
varied intraglanular porosity are future promising options as bone grafts substitute. Most of 
the commonly used and under trial bone graft substitutes only have osteoconductive and 
osteogenic characters. Therefore, it is of paramount necessity to develop an ideal novel 
smart biomaterials with all three properties which cannot only provide sufficient 
concentration of antibiotic at the target site but also act as a bone strut to accelerate the goal. 
This may be achieved by combining conventional and some unconventional growth factors 
with the carrier materials including the incorporation of stem cells (Nandi et al, 2009). 
The necessary data on the efficacy of these new biodegradable materials still are in early 
stages of development and assessment. Despite the vast potential to develop composite 
biomaterials that can provide multiple functions, the complexity of the cellular and 
molecular interactions within the wound environment exposes the potential for 
unforeseen adverse consequences. In fact, many of the clinical scenarios of treatment of 
musculoskeletal infection include the need for local antibiotics and stimulation of the 
process of bone regeneration. One of the most obvious adverse effects of high level of 
local antibiotics is an osteoblast function and subsequent bone regeneration. The concern 
is valid for specific clinical situations such as antibiotic bead pouches for treatment of 
open fractures (Henry et al, 1993b), bone grafting for nonunions, and implantation of 
devices into bone defects where bone regeneration is an intended outcome of the dead-
space management strategy (Gitelis & Brebach, 2002). 
5. Conclusion 
The appropriate use of antimicrobial agents has decreased morbidity and mortality from 
orthopedic-related infections. Although systemic antibiotic use has been used for many years, 
new methods of local antibiotic delivery may result in increased antibiotic levels, decreased 
toxicity, and possibly greater efficacy. Antibiotic impregnated polymethylmethacrylate beads 
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are currently being used in a variety of applications, but this method require a second 
procedure for removal of the antibiotic delivery system. 
There is considerable interest in finding methods of delivering effective doses of 
antimicrobial drugs locally, not only in orthopedics, but across a range of specialists. While 
most of the antibacterial agent contained within a biodegradable system may be eluted, only 
25% is actually released from polymethylmethacrylate beads. Biodegradable materials could 
mimic bone substances like calcium phosphate based carriers can be chosen for local drug 
delivery system in osteomyelitis with potential clinical application in orthopedic surgery. 
Widespread research is currently being conducted in the area of local drug delivery systems 
to treat osteomyelitis. Despite this fact, much work is still desired in the areas of 
biodegradable and biocompatible materials, the kinetics of antibiotic release, and further 
development of current systems before many of these formulations can be used. The seer 
diversity of available systems and the lack of suitable trials comparing them in-vivo makes 
their evaluation difficult. Nonetheless, it is apparent that while collagen fleece is currently 
the most widely used antimicrobial carrier system, the duration of its antibiotic delivery is 
the shortest. Other delivery systems have shown greater promise, and these that are able 
both to stimulate the formation of new bone and provide a scaffold, such as composite 
antibiotic carriers, are most likely to gain widespread acceptance in the future. 
In future, researchers remain optimistic that many of these systems can be developed with 
ideal zero-order release kinetics profiles, in-vivo, over long periods of time, allowing for 
widespread use in chronic osteomyelitis patients. By utilizing newer forms of sustained-
release antibiotic delivery systems, it will be possible to deliver such antibiotics at 
constant rates over a prolonged period of time and would eliminate the need for multiple 
dosing. It is hoped that in the future, development of new implantable systems would be 
helpful to reduce the cost of drug therapy, increase the efficacy of drugs, and could 
enhance the patient’s compliance. 
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